文献速递骨软组织肉瘤与黑色素瘤

Euro-EWING99研究长期分析:尤文肉瘤患者特征与结局

Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study.
PubMed 文献 · J Clin Oncol · 2026-07-31

中位随访7.2年,全队列3年和5年PFS分别为60.2%和55.4%,OS分别为72.6%和64.6%。除转移状态外,年龄、肿瘤体积和新辅助治疗后组织学反应是独立预后因素。

要点

  • 全队列3年PFS 60.2%、5年PFS 55.4%;3年OS 72.6%、5年OS 64.6%。
  • 转移状态、年龄、肿瘤体积和组织学反应均为PFS和OS的独立预后因素。
  • 新辅助治疗后完全组织学反应具有重要预后价值。

核心结论

  • 该研究是已发表的最大尤文肉瘤患者系列,证实新辅助治疗后完全组织学反应具有重要预后价值。

研究设计与样本

  • 患者接受6周期VIDE方案诱导化疗(每3周),随后局部治疗(手术/放疗),并按临床危险组和试验接受不同巩固治疗。

主要发现

  • 全队列中位随访7.2年,3年和5年PFS分别为60.2%和55.4%,3年和5年OS分别为72.6%和64.6%。
  • 除诊断时转移状态外,年龄、肿瘤体积和组织学反应均为PFS和OS的独立预后因素。

临床怎么用

  • 尤文肉瘤风险分层与预后评估应综合考虑诊断时转移状态、年龄、肿瘤体积及新辅助治疗后组织学反应。
  • 新辅助化疗后组织学反应可作为后续风险适配治疗决策的重要参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Euro-EWING99 study was a large, international, prospective study recruiting patients with Ewing sarcoma (EWS) between 1999 and 2015. It assessed three different clinical questions through randomized trials. We report here the characteristics and outcomes of all patients. METHODS: Patients younger than 50 years with EWS were included in the study. They received induction chemotherapy (six courses of vincristine [day 1], ifosfamide [day 1-3], doxorubicin [day 1-3], and etoposide [day 1-3; VIDE], administered every 3 weeks), local therapy (surgery/radiotherapy), and different consolidation treatments according to clinical risk group and trial.The objectives of the study were to describe the entire cohort according to the initial staging group, to describe the survival outcomes (overall survival [OS]; progression-free survival [PFS]; and local control), and to evaluate prognostic factors associated with OS and PFS. RESULTS: Three thousand three hundred ninety-five patients were included in the study, including 2,267 with a localized disease, 614 with pleuropulmonary metastases, and 514 with extrapulmonary metastases. Ninety-eight percent of patients received ≥4 neoadjuvant VIDE courses. The modalities of local treatment and consolidation therapy differed among the three staging groups. With a median follow-up of 7.2 years, PFS of the entire cohort was 60.2% and 55.4% at 3 and 5 years, respectively. OS was 72.6% and 64.6% at 3 and 5 years, respectively. In addition to metastatic status at diagnosis, main prognostic factors included patient age, tumor volume, and histologic response both for PFS and OS, independent of metastatic status. CONCLUSION: To our knowledge, this study is the largest published series of patients with EWS and may serve as a landmark paper for EWS. It confirms the major prognostic value of the complete histologic response after neoadjuvant therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Valentin T, Winter S, Dirksen U, et al. Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study. J Clin Oncol. 2026. PMID: 42537000. doi:10.1200/JCO-25-02516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。